Stocks›Healthcare›PCRX

PCRX

Pacira Biosciences, Inc.

NasdaqResearch view

Pacira Biosciences, Inc. operates in the Pharmaceutical Preparations industry.

$25.20+1.78%

Oct 7 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsSmall-capSEC EDGAR FY 2025-12-31

On the Wire · latest 1

All stories →

Oct 8 · PR NewswireViatris agrees to buy Pacira, adding EXPAREL and ZILRETTAViatris agreed to acquire Pacira BioSciences, adding EXPAREL and ZILRETTA to its portfolio of non-opioid pain medicines. The transaction creates a larger commercial platform for Pacira’s marketed products, but its value depends on closing and on Viatris expanding their reach.

On the Wire · latest 1

All stories →

Oct 8 · PR NewswireViatris agrees to buy Pacira, adding EXPAREL and ZILRETTAViatris agreed to acquire Pacira BioSciences, adding EXPAREL and ZILRETTA to its portfolio of non-opioid pain medicines. The transaction creates a larger commercial platform for Pacira’s marketed products, but its value depends on closing and on Viatris expanding their reach.

What happened

Daily closes · dots are Wire stories

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 6, 2025 and Nov 6, 2024, after the close.

Last report

Aug 4, 2026−9.96%

after the close

Last 4, next close

median 6.85% either way

up 0 of 4

Every report since 2023 →Earnings calendar →

DateEventSourceNext close

Aug 4Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗−9.96%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

What happened · big days

11 big days in a year, and what we hold on each

A big day is a close more than 4.46% from the one before, three times PCRX’s median day (1.49%). On 1 of the 11, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.

every other trading daya big day, numbered in the list below±4.46%Hover a bar for its day. Click a big day to open it.

Shaded: since our stories began, Jun 10. Tap a bar for its day.

#DayPCRXWhat we hold that dayGroup (median of 4) · each

1 Nov 7, 2025+4.50%
Resultsgroup −0.1%, did not move with it
1Nov 7, 2025+4.50%
ResultsFirst close after the Nov 6 results filing
−0.1% did not move with itMRK +0.6 · ABBV +0.1 · JNJ −0.2 · LLY −1.4
2 Nov 10, 2025+4.63%
Before our storiesgroup +0.8%, did not move with it
2Nov 10, 2025+4.63%
Before our stories
+0.8% did not move with itLLY +4.6 · JNJ +1.0 · MRK +0.5 · ABBV −0.2
3 Nov 11, 2025+4.55%
Before our storiesgroup +2.9%, moved with PCRX
3Nov 11, 2025+4.55%
Before our stories
+2.9% moved with PCRXMRK +4.8 · ABBV +3.0 · JNJ +2.9 · LLY +2.3
4 Nov 20, 2025−6.29%
Before our storiesgroup −0.3%, did not move with it
4Nov 20, 2025−6.29%
Before our stories
−0.3% did not move with itABBV −1.5 · LLY −0.6 · MRK −0.1 · JNJ +0.3
5 Jan 2, 2026−5.49%
Before our storiesgroup +0.5%, did not move with it
5Jan 2, 2026−5.49%
Before our stories
+0.5% did not move with itJNJ +0.2 · ABBV +0.4 · LLY +0.5 · MRK +1.1
6 Jan 9, 2026−9.57%
Resultsgroup −1.2%, did not move with it
6Jan 9, 2026−9.57%
ResultsFirst close after the Jan 8 results filing
−1.2% did not move with itLLY −2.0 · ABBV −1.8 · JNJ −0.7 · MRK −0.4
7 Jan 13, 2026−5.80%
Before our storiesgroup −0.0%, did not move with it
7Jan 13, 2026−5.80%
Before our stories
−0.0% did not move with itMRK −0.8 · LLY −0.3 · ABBV +0.3 · JNJ +1.9
8 Jan 15, 2026−7.15%
Before our storiesgroup −1.2%, did not move with it
8Jan 15, 2026−7.15%
Before our stories
−1.2% did not move with itLLY −3.8 · ABBV −2.3 · MRK −0.0 · JNJ +0.5
9 Jan 16, 2026−7.22%
Before our storiesgroup −0.8%, did not move with it
9Jan 16, 2026−7.22%
Before our stories
−0.8% did not move with itMRK −1.9 · ABBV −1.1 · JNJ −0.4 · LLY +0.5
10 Jan 21, 2026+4.87%
Before our storiesgroup +1.3%, did not move with it
10Jan 21, 2026+4.87%
Before our stories
+1.3% did not move with itLLY +3.6 · MRK +1.5 · ABBV +1.0 · JNJ −0.1
11 Aug 5, 2026−9.96%
Resultsgroup +1.0%, did not move with it
11Aug 5, 2026−9.96%
ResultsFirst close after the Aug 4 results filing
+1.0% did not move with itMRK +0.3 · ABBV +1.0 · JNJ +1.0 · LLY +4.9

A story on the same day is not a cause, and a group move is not proof either. Group: the median of LLY, JNJ, ABBV and MRK that day, the largest companies in PCRX’s SEC industry; “moved with PCRX” means the same direction and at least half the size.

What’s next · results

Before the next report: what the first day after the last four did

Six trading days after each results filing (SEC 8-K, Item 2.02). PCRX reports after the close, so day 1 is the next close. Each time, day 6 ended on the same side as day 1.

Reported Jan 8, 2026

day 1−9.57%day 6−26.36%

Reported Feb 26, 2026

day 1−3.01%day 6−2.61%

Reported Apr 30, 2026

day 1−4.12%day 6−9.18%

Reported Aug 4, 2026

day 1−9.96%day 6−14.19%

Next report: expected early NovemberEstimated from the dates of its last four results filings. Not announced. Since the Aug 4 report: −8.76%. Four reports is a small sample.

Every report since 2023 →

Each line is PCRX’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.

The numbers · FY2025, filed

SEC EDGAR

Market cap$1.0B

Revenue$726.4M+3.60%

Net income$7.0M

EPS, diluted$0.16+107.40%

Operating margin2.6%

Return on equity1.0%

Debt / equity0.54

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$1.0B

Enterprise Value$1.2B

Income$7.0M

Sales$726.4M

Book/sh$17.39

Cash/sh$3.98

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio3.28

Current Ratio4.54

Debt/Eq0.54

EPS (ttm)$0.16

EPS this Y107.4%

EPS past 3/5Y-22.2%

Sales past 3/5Y2.9%

EPS Y/Y TTM107.4%

Sales Y/Y TTM3.6%

Shs Outstand39.86M

ROA0.6%

ROE1.0%

ROIC0.9%

Gross Margin—

Oper. Margin2.6%

Profit Margin1.0%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$541.5M

FY21

$666.8M

FY22

$675.0M

FY23

$701.0M

FY24

$726.4M

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$541.5M	$666.8M	$675.0M	$701.0M	$726.4M
Gross Profit	—	—	—	—	—
Operating Income	$89.9M	$60.0M	$87.7M	$-73.4M	$19.2M
Net Income	$42.0M	$15.9M	$42.0M	$-99.6M	$7.0M
Diluted EPS	$0.92	$0.34	$0.89	$-2.15	$0.16
Operating Cash Flow	$125.7M	$145.3M	$154.6M	$189.4M	$152.0M
Free Cash Flow	$79.9M	$115.2M	$139.5M	$178.8M	$136.7M

Same industry

PCRX against four drug peers, a year at 100

PCRX is up 12.8% in a year. Merck is up 66.1%, Eli Lilly 42.6%, Johnson & Johnson 35.5% and AbbVie 17.7%. All four did more. Weekly closes, Oct 10, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

PCRX +12.8%. Merck +66.1%, Eli Lilly +42.6%, Johnson & Johnson +35.5%, AbbVie +17.7%. Weekly closes, Oct 10, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in PCRX’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

Same industry

In the screener →

LLY$1.12T JNJ$622.8B ABBV$479.5B MRK$352.3B ABT$170.8B PFE$159.6B VRTX$128.2B BMY$122.0B

Follow the news. Track the move.

PCRX story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Market context

Oct 8

Viatris agrees to buy Pacira, adding EXPAREL and ZILRETTA

Viatris agreed to acquire Pacira BioSciences, adding EXPAREL and ZILRETTA to its portfolio of non-opioid pain medicines. The transaction creates a larger commercial platform for Pacira’s marketed products, but its value depends on closing and on Viatris expanding their reach.

Price history unavailable

PR Newswire · 7h ago

View both sides →